Results of the global phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor Alpelisib ( BYL719 ) has met the primary endpoint showing an improvement in progression-free survival ( PFS ), were presented.
SOLAR-1 is evaluating Alpelisib in combination with Fulvestrant compared to Fulvestrant alone in postmenopausal women and men with hormone-receptor positive, human epidermal growth factor receptor-2 negative ( HR+/HER2- ) PIK3CA-mutant advanced or metastatic breast cancer that progressed on or following aromatase inhibitor treatment with or without a CDK4/6 inhibitor.
Currently, there are no approved PI3K inhibitors for HR+ advanced breast cancer. The PI3K pathway plays an important role in regulating cell processes and is the most frequently altered pathway promoting tumor growth, disease progression and treatment resistance in HR+ advanced breast cancer.
Adverse events observed with Alpelisib in combination with Fulvestrant in SOLAR-1 were generally consistent with those observed in previous Alpelisib and Fulvestrant studies.
The SOLAR-1 trial will continue to assess data for secondary endpoints.
Studies have established the role of PI3K signaling in several processes critical for cancer progression, including cell metabolism, growth, survival and motility.
Activation of the PI3K pathway in breast cancer is associated with resistance to endocrine therapy, disease progression and poorer prognosis.
Proteins in the PI3K pathway consist of four smaller parts called isoforms. Approximately 40% of HR+ advanced breast cancer patients have genetic mutations that activate the alpha isoform, called PIK3CA mutations. Mutations in the three other isoforms are typically not associated with advanced breast cancer.
SOLAR-1 is a phase III randomized, double-blind, placebo-controlled trial studying Alpelisib in combination with Fulvestrant for postmenopausal women and men with PIK3CA-mutated HR+/HER2- advanced or metastatic breast cancer that progressed on or following prior aromatase inhibitor treatment with or without a CDK4/6 inhibitor.
The trial randomized 572 patients in a 1:1 ratio to receive continuous oral treatment with Alpelisib 300mg or placebo once daily in combination with Fulvestrant 500mg intramuscular injections on days 1 and 15 on the first cycle and day 1 of each subsequent 28-day cycle as per Fulvestrant prescribing information.
Patients were allocated based on tumor tissue assessment to either a PIK3CA-mutant cohort or a PIK3CA non-mutant cohort.
Stratification was based on visceral metastases and prior CDK4/6 inhibitor treatment.
The primary endpoint is progression-free survival for patients with the PIK3CA mutation. Secondary endpoints include but are not limited to: overall survival, overall response rate, clinical benefit rate, health-related quality of life, efficacy in PIK3CA non-mutant cohort, safety and tolerability.
Alpelisib is an investigational, orally bioavailable, alpha-specific PI3K inhibitor. In breast cancer cell lines harboring PIK3CA mutations, Alpelisib has been shown to potentially inhibit the PI3K pathway and have antiproliferative effects.
In addition, cancer cell lines with PIK3CA mutations were more sensitive to Alpelisib than those without the mutation across a broad range of different cancers. ( Xagena )
Source: Novartis, 2018